WELCOME TO The Biotechnology REPORT
NorCal-Gene Therapy and Research
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
BioSpace | March 02, 2020
BioDuro LLC, a leading global life sciences contract research and development organization, announced today that it has broadly launched new antibody- and cell-based therapy discovery services. The services have already been validated by early-access partners that have advanced several biologics-based therapies into the clinic. The Biologics Discovery team at BioDuro has more than 40 scientists and is led by a pharma- and biotech-experienced team with more than 100 years of combined biologics ex...
Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug...
Palantir Technologies Inc. | December 21, 2021
Palantir Technologies Inc. a leading builder of operating systems for the modern enterprise, and Dewpoint Therapeutics the leading biomolecular condensates company, announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.
Palantir Foundry will help to enable researchers at Dewpoint to further their understanding of condensates biology by analyzing lab data along with oth...
Express Healthcare | April 02, 2020
The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE